Matthew D Coates
Overview
Explore the profile of Matthew D Coates including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coates M, Walter V, Stuart A, Small J, Dalessio S, Carkaci-Salli N, et al.
Clin Transl Gastroenterol
. 2024 Dec;
15(12):e00778.
PMID: 39729348
Introduction: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073 val/val ) related...
2.
Du Y, Spencer A, Roy P, Abdulhamid A, Dalessio S, Levenick J, et al.
Dig Dis Sci
. 2024 Dec;
70(2):462-468.
PMID: 39694991
Gastroesophageal reflux disease (GERD) is a very common condition characterized by chronic symptoms, such as heartburn or epigastric and/or substernal pain, that are frequently associated with mucosal damage resulting from...
3.
Glickman D, Dalessio S, Raup-Konsavage W, Vrana K, Coates M
Inflamm Bowel Dis
. 2024 Oct;
30(12):2531-2532.
PMID: 39361966
No abstract available.
4.
Anderson B, Sepulveda D, Nachnani R, Cortez-Resendiz A, Coates M, Beckett A, et al.
J Pharmacol Exp Ther
. 2024 Jul;
390(3):331-341.
PMID: 39009468
L. has a long history of medicinal use, particularly for gastrointestinal diseases. Patients with inflammatory bowel disease (IBD) report using cannabis to manage their symptoms, despite little data to support...
5.
Heinle J, Dalessio S, Janicki P, Ouyang A, Vrana K, Ruiz-Velasco V, et al.
Front Pharmacol
. 2024 Jun;
15:1398409.
PMID: 38855747
Pain is a major issue in healthcare throughout the world. It remains one of the major clinical issues of our time because it is a common sequela of numerous conditions,...
6.
Kader L, Willits A, Meriano S, Christianson J, La J, Feng B, et al.
J Pain
. 2024 May;
25(9):104572.
PMID: 38768798
Chronic abdominal pain in the absence of ongoing disease is the hallmark of disorders of gut-brain interaction (DGBIs), including irritable bowel syndrome (IBS). While the etiology of DGBIs remains poorly...
7.
Kapur M, Soliman M, Blanke E, Herold P, Janicki P, Vrana K, et al.
Neurogastroenterol Motil
. 2024 Jan;
36(3):e14748.
PMID: 38263802
Background: Silent inflammatory bowel disease (IBD) is a condition in which individuals with the active disease experience minor to no pain. Voltage-gated Na (Na ) channels expressed in sensory neurons...
8.
Ba D, Yadav S, Liu G, Leslie D, Vrana K, Coates M
Sci Rep
. 2024 Jan;
14(1):1060.
PMID: 38212393
Antidepressant medications (AMs) are frequently used in inflammatory bowel disease (IBD). Many AMs enhance serotonin (5-HT) availability, but this phenomenon may actually worsen IBD. We hypothesized that use of 5-HT-enhancing...
9.
Coates M, Dalessio S, Stuart A, Walter V, Tinsley A, Clarke K, et al.
Inflamm Intest Dis
. 2023 Dec;
8(4):153-160.
PMID: 38115910
Introduction: Hypoalgesic or silent inflammatory bowel disease (IBD) is a poorly understood condition that has been associated with poor clinical outcomes. There is evidence that lifestyle factors, including diet, exercise,...
10.
Bogale K, Zubrzycka I, Stuart A, Cesaire M, Walter V, Tinsley A, et al.
Ann Gastroenterol
. 2023 Nov;
36(6):630-636.
PMID: 38023977
Background: Polysubstance use (PSU), the simultaneous use of 2 or more substances of abuse, is common in inflammatory bowel disease (IBD). Preliminary studies suggest it may be associated with poor...